Post-Approval Change Management On A Global Scale: An Inconvenient Complexity For Pharma?
This article was originally published in SRA
Executive Summary
Managing the post-approval regulatory change process for pharmaceuticals at the global level is complex, unpredictable and time consuming because of regional differences and frequent changes in procedures, requirements and timelines. More international harmonization of legislation relating to post-approval changes would help to increase regulatory compliance and to support continuous improvement and optimization of manufacturing and control processes, say Julia Radzihovsky, Claus-Dieter Schiller, Ralf Gleixner and Barbara Jentges.
You may also be interested in...
Finance Watch: Five More Small IPOs Squeeze Through The US Window
Public Company Edition: Genenta, Cingulate, ImmixBio, Bionomics and NeuroSense launched initial public offerings, grossing just $118m between them. But Amylyx, with a recently filed ALS drug, has filed to raise up to $100m. In follow-on offerings, Legend took advantage of ASH goodwill to raise $300m.
Deal Watch: BMS Licenses Bispecific TCR Candidate From Immatics
BioMarin teams with Skyline on gene therapies for cardiovascular disease. Myrtelle discloses licensing of gene therapy for Canavan disease from Pfizer earlier in 2021.
Label Comprehension Results Point Petros Toward OTC Self-Selection Study For Stendra ED Drug
Petros considers switch NDA for Stendra (avanafil), approved for Rx sales in US since 2012 on an NDA by Metuchen. Early indicators showed positive outcomes in a 453-subject label comprehension study for the oral PDE5 inhibitor.